Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis
Recruiting in Palo Alto (17 mi)
+16 other locations
Overseen byLawrence Parish, MD
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Merz North America, Inc.
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
A research study to compare the safety and effectiveness of an investigational medication called NAFT-500 to placebo, when used in subjects with tinea pedis (athlete's foot).
Eligibility Criteria
Inclusion Criteria
Review and sign a statement of Informed Consent and HIPAA authorization.
For minors (less than 18 years), the parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).
Males or non-pregnant females ≥12 years of age, of any race or sex. Females of childbearing potential must have a negative urine pregnancy test.
See 4 more
Treatment Details
Interventions
- NAFT-500 (Antifungal Agent)
- Naftin 1% (Antifungal Agent)
- Placebo 2-weeks (Drug)
- Placebo 4-weeks (Drug)
Participant Groups
4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: 1Experimental Treatment1 Intervention
Naftin 2% cream applied daily for 2 weeks
Group II: 3Active Control1 Intervention
Active comparator applied daily for 4 weeks
Group III: 2Placebo Group1 Intervention
Placebo cream applied daily for two weeks
Group IV: 4Placebo Group1 Intervention
placebo cream applied daily for 4 weeks
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Paddington Testing CompanyPhiladelphia, PA
J & S StudiesCollege Station, TX
Zoe Draelos, MDHigh Point, NC
Temple University School of Podiatric MedicinePhiladelphia, PA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Merz North America, Inc.Lead Sponsor